Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
Comments (0)Posts tagged: alexza
Comments (0)Alexza Pharmaceuticals Files Shelf Registration Statement
MOUNTAIN VIEW, Calif. , May 4 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow the Company to sell, from time to ...
Alexza to Announce 2010 First Quarter Financial Results on Monday, May 10, 2010
MOUNTAIN VIEW, Calif. , April 29 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it will report results for its fiscal quarter ended March 31, 2010 , on Monday, May 10, 2010 following the close of the U.S. financial markets. The Company ...
Alexza Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
...
30th, alexza, care, company, conference, cowen, health, pharmaceuticals, present
Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
MOUNTAIN VIEW, Calif. , Feb. 16 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it will host an investor/analyst meeting on Thursday, February 18, 2010 from 9:00 a.m. - 12:00 p.m. ET , in New York City . ...
Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010
MOUNTAIN VIEW, Calif. , Feb. 11 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that the U.S. Food & Drug Administration has accepted the AZ-004 NDA for filing and has indicated a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010 . ...
FDA accepts Alexza Pharmaceuticals’ AZ-004 NDA
Alexza Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration has accepted the AZ-004 NDA for filing and has indicated a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010.
Alexza and Biovail Form Collaboration to Develop and Commercialize AZ-004 (Staccato(R) Loxapine) in North America
MOUNTAIN VIEW, Calif. , Feb. 10 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation (NYSE: BVF ), to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and ...
Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International
Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza ...